The European Forum for Good Clinical Practice  (EFGCP) and MedTech Europe, the alliance of European medical technology industry  associations, today announce the establishment of a joint Medical Technology.  Working Party within EFGCP aimed at addressing ethical and quality issues when  setting standards for clinical evaluation in the medical technology sector.

  Setting effective ethical and quality clinical standards for medical technology is critical to ensuring that  patients have access to safe and effective treatment. The joint EFGCP-MedTech Europe “Medical  Technology Working Party” will seek to involve stakeholders in a dialogue on making sure these  standards are broadly accepted and reliably introduced in the rapidly developing, diverse medical  technology landscape.

  “Historically, the clinical development debate has focused on pharmaceuticals,” said EFGCP Chair  Ingrid Klingmann, “but it’s important that we have a deeper conversation about issues that need to be  considered when setting standards for the medical technology sector.”

  The working party hopes to attract a broad group of expert stakeholders including patient advocates,  physician groups, academics, ethics committees, competent authorities and medtech and pharma  industry representatives to collect views on good clinical practice, quality and ethical issues as they  pertain to medical technology and provide recommendations to policy-makers. MedTech Europe CEO  Serge Bernasconi said: “There’s a growing understanding in the healthcare policy arena that we can’t  just copy and paste the pharmaceutical approach to clinical standards into EU legislation on medical  devices and in vitro diagnostics. Only with a vibrant dialogue can we figure out which direction is right  for medical technology and above all, for the patient.”

  The working group will initially organise a joint workshop on Mitigating Risks in the Lifecycle of Medical  Devices: Options and Challenges in the Medical Device Legislation. The workshop, to be held on 4  December in Brussels, will bring together patients, national competent authorities, ethics committees,  lab technicians, healthcare professionals, industry representatives and European regulatory authorities  with the aim of finding consensus on key topics of interest and potential policy recommendations.

There will be a separate discussion specifically on in vitro diagnostics and particular considerations  related to the proposed IVD Regulation, with the view to organising a high-level, multi-stakeholderroundtable and assess the key concerns.

News

New multi-stakeholder collaboration will drive dialogue on specificities of clinical standards for medical technology